Ocelot Bio Closes $36 Million Series A Financing, Appoints Katherine Vega Stultz As President And Chief Executive Officer
Amount Raised
$36 Million
Round Type
Series A
San DiegoBiotechnologyHealthcareHealth CareDescription
Ocelot Bio, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics to treat complications of end-stage liver disease (ESLD), today announced the close of a $36 million Series A financing led by RA Capital Management, Venrock and Vivo Capital and the appointment of Katherine Vega Stultz, an experienced pharmaceutical and biotech executive, as president and chief executive officer. Ocelot Bio recently received clearance from the U.S. Food & Drug Administration (FDA) for its Investigational New Drug (IND) application and will initiate a Phase 2 trial with lead candidate OCE-205 for the treatment of hepatorenal syndrome with acute kidney injury (HRS-AKI).
Quick answer
Ocelot Bio raised $36 Million in a Series A round, dated March 23, 2022. Ocelot Bio is based in San Diego, California, United States.
- How much did Ocelot Bio raise?
- Ocelot Bio raised $36 Million in a Series A round on March 23, 2022.
- What does Ocelot Bio do?
- Ocelot Bio is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics designed to significantly improve outcomes for patients with liver disease.
- Where is Ocelot Bio based and how big is it?
- Ocelot Bio is based in San Diego, California, United States.
- Who are the decision-makers at Ocelot Bio?
- Fundz holds 1 contact at Ocelot Bio. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Biotechnology around the same time
Companies in the same sectors as Ocelot Bio that raised within 45 days of this round, from Fundz verified event records.
- Nuo Therapeutics raised $3.5M on May 6, 2022.
- Treace raised $150M (Debt Financing) on May 2, 2022.
- Zetagen Therapeutics raised $9.6M on April 29, 2022.
- CytoDyn raised $1.9M (Seed) on April 22, 2022.
- Optimize Systems raised $2M (Seed) on April 19, 2022.
- Flyte raised $75K (Seed) on March 31, 2022.
Who to call at Ocelot Bio, and when
A new round usually means Ocelot Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Ocelot Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Ocelot Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Ocelot Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Ocelot Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansOcelot Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.